145325-40-2

Basic information

• Product Name: 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER;METHYL 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLATE;Methyl 4-broMothieno[2,3-...;Thieno[2,3-c]pyridine-2-carboxylic acid, 4-broMo-, Methyl ester
• CAS NO: 145325-40-2
• Molecular Formula: C₉H₆BrNO₂S
• Molecular Weight: 272.12
• Product Categories: Building Blocks;Thieno[x,x-y]pyridine
• Mol File: 145325-40-2.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 372.662 °C at 760 mmHg
• Flash Point: 179.18 °C
• Appearance: /
• Density: 1.697 g/cm³
• Vapor Pressure: 9.46E-06mmHg at 25°C
• Refractive Index: 1.672
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.21±0.40(Predicted)
• CAS DataBase Reference: 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(145325-40-2)
• EPA Substance Registry System: 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER(145325-40-2)

Safety Data

• Hazardous Substances Data: 145325-40-2(Hazardous Substances Data)

Usage

General Description

4-Bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester is a chemical compound with the molecular formula C9H6BrNO2S. It is a methyl ester derivative of 4-bromothieno[2,3-c]pyridine-2-carboxylic acid and is often used as a starting material in the synthesis of various bioactive compounds and pharmaceuticals. 4-BROMOTHIENO[2,3-C]PYRIDINE-2-CARBOXYLIC ACID METHYL ESTER is a heterocyclic aromatic ring system that contains a bromine atom, a carboxylic acid group, and a methyl ester group. It is commonly used in organic chemistry research and pharmaceutical development due to its potential therapeutic and biological activities. Additionally, it is important to handle and store this compound in accordance with proper safety guidelines and regulations. Please note that this is a general summary and additional specific information may be required when working with this chemical compound.

InChI:InChI=1/C9H6BrNO2S/c1-13-9(12)7-2-5-6(10)3-11-4-8(5)14-7/h2-4H,1H3

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 2365-48-2 Methyl thioglycolate 
• 70201-42-2 3,5-dibromopyridine-4-carboxaldehyde 

Downstream Products

• 870243-58-6 methyl thieno[2,3-c]pyridine-2-carboxylate 
• 478149-00-7 thieno[2,3-c]pyridine-2-carboxylic acid 
• 1296224-08-2 4-bromothieno[2,3-c]pyridine 
• 1151512-25-2 4-bromothieno[2,3-c]pyridine-2-carboxylic acid 
• 870238-39-4 4-bromo-7-chloro-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 
• 1153577-15-1 C₂₁H₁₅NO₂S 
• 870243-94-0 (4-bromo-thieno[2,3-c]pyridin-2-yl)-methanol 

Relevant articles and documents

Synthesis of thieno[2,3-c]pyridine derived GRK2 inhibitors

Bicyclic heteroaromatic motifs with hydrogen bond donor–acceptor hinge binder motifs are frequently used as ATP-mimetic kinase inhibitors. Althought the thieno[2,3-c]pyridine scaffold also meets these criteria its use was limited so far by the availability of synthetic building blocks. Inspired by two X-ray structures of kinase bound thieno[2,3-c]pyridines we prepared a diverse collection of simple thieno[2,3-c]pyridine derivatives that could serve as starting points for future drug discovery programs. In our search for inhibitors of the GRK2 kinase we also identified a hit compound bearing the thieno[2,3-c]pyridine moiety. Following a structure-driven optimization process a collection of potent and highly ligand efficient inhibitors were prepared and characterized, which could form the basis of a future drug discovery program. Graphical abstract: [Figure not available: see fulltext.]

AMPK INHIBITORS

The 5'-AMP-activated protein kinase AMPK functions as a master switch to maintain cellular and whole-body energy homeostasis and abnormal activity profiles of AMPK may cause pathological disorders. The present invention relates to a series of compounds (I

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.